Gilead Sciences (NASDAQ:GILD) CEO Sells $1,398,900.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the transaction, the chief executive officer directly owned 556,698 shares in the company, valued at $77,876,483.22. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $141.95 on Friday. The business’s 50-day moving average is $125.36 and its 200 day moving average is $119.67. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $142.20. The company has a market capitalization of $176.11 billion, a P/E ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm earned $2.02 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. GoalVest Advisory LLC grew its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $27,000. Ares Financial Consulting LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $28,000. Finally, Financial Consulate Inc. raised its holdings in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Rothschild & Co Redburn raised their price target on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Finally, Daiwa Capital Markets raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $136.73.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.